Hengrui Pharma responded to the rumors of anti-corruption storm involving medicine: there is no network transmission, and the operation and management are normal. On August 1 day, some investors in Hengrui Pharma asked whether the company's sales expenses were used in compliance. Hengrui Pharma responded on August 3rd that please pay attention to the notes to the company's financial statements for sales expense information.
The company has always attached importance to the development of sales compliance, always strictly adhered to the compliance bottom line, constantly strengthened the assessment of the sales team's code of conduct, and constantly improved the compliance awareness of sales staff.
In fact, the rumor that "the Shenzhen office was copied" attracted attention on August 2, when Hengrui Pharma told the reporter of the Herald that after verification, the company, its subsidiaries and all its accredited institutions did not have such a situation at present.
In response to the above questions, Hengrui Pharma responded on the interactive platform on August 7 that the company, its subsidiaries and all its accredited institutions have no online communication, and the short-term stock price fluctuation in the secondary market is affected by multiple factors, and the daily management and operation of the company are all normal.
Development history
Lianyungang Pharmaceutical Factory, the predecessor of Hengrui Pharma, was formally established on 1970. In 2000, Hengrui Pharma was listed on the Shanghai Stock Exchange. Shanghai Hengrui R&D Center was established. On April 27th, 2022, Hengrui Pharma announced that the company had recently received the Notice of Approval for Clinical Trials of Irinotecan Hydrochloride Liposome Injection from the State Administration of Pharmaceutical Products, and would conduct clinical trials in the near future.
On the evening of May 17, 2022, according to the announcement of Hengrui Pharma, its subsidiaries, Shanghai Sheng Di Pharmaceutical Co., Ltd. and Suzhou Shengdiya Biomedical Co., Ltd., received the Notice of Approval for Clinical Trials of Ademab Injection and SHR-8068 Injection approved by the State Administration of Pharmaceutical Products, and will conduct clinical trials in the near future.
Reference to the above content: Baidu Encyclopedia-jiangsu hengrui Pharmaceutical Co., Ltd.